135 results found.

Multiple Myeloma Clinical Trial using Adoptive Immunotherapy; Th1/Tc1 product

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Multi-Center Phase I Study of Th1/Tc1 Immunotheraphy Following Autologous Hematopoietic Progenitor Cell Transplantation in High Risk Multiple Myeloma.
Adoptive Immunotherapy; Th1/Tc1 product

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using MV-NIS; cyclophosphamide; I-123 prior MV-NIS; I-123 post MV-NIS; Liothyronine

Mayo Clinic - Recruiting 18 years or older.
- Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma.
MV-NIS; cyclophosphamide; I-123 prior MV-NIS; I-123 post MV-NIS; Liothyronine

Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bon Clinical Trial using Denosumab; Zoledronic acid

Amgen - Recruiting 18 years or older.
- A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometar) in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma.
Denosumab; Zoledronic acid

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using carfilzomib; dexamethasone; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2).
carfilzomib; dexamethasone; laboratory biomarker analysis

Myeloma Clinical Trial using Pomalidomide; Dexamethasone; G-CSF; Phone Calls

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma.
Pomalidomide; Dexamethasone; G-CSF; Phone Calls

Multiple Myeloma Clinical Trial using lenalidomide; pidilizumab; pharmacological study; laboratory biomarker analysis

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma.
lenalidomide; pidilizumab; pharmacological study; laboratory biomarker analysis

Stage I Multiple Myeloma, Stage II Multiple Myeloma, or Stage III Clinical Trial using ixazomib; cyclophosphamide; dexamethasone; pharmacological study; questionnaire administration; quality-of-life assessment

Mayo Clinic - Recruiting 18 years or older.
- Phase 1/2 Trial of MLN9708 in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma.
ixazomib; cyclophosphamide; dexamethasone; pharmacological study; questionnaire administration; quality-of-life assessment

Myeloma Clinical Trial using Thalidomide; Lenalidomide; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Thalidomide; Lenalidomide; Questionnaires

Multiple Myeloma Clinical Trial using DFRF4539A

Genentech - Recruiting 18 years or older.
- An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma.
DFRF4539A

Leukemia, Lymphoma, or Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Refractory Multiple Myeloma Clinical Trial using pomalidomide; bortezomib; dexamethasone; laboratory biomarker analysis; gene expression analysis

Mayo Clinic - Recruiting 18 years or older.
- MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
pomalidomide; bortezomib; dexamethasone; laboratory biomarker analysis; gene expression analysis

Refractory Multiple Myeloma Clinical Trial using bendamustine hydrochloride; lenalidomide; dexamethasone

Mayo Clinic - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
bendamustine hydrochloride; lenalidomide; dexamethasone

Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Ly Clinical Trial using Dasatinib

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Mul Clinical Trial using Dasatinib; laboratory biomarker analysis

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib; laboratory biomarker analysis

Multiple Myeloma Clinical Trial using high dose dexamethsone

Yonsei University - Recruiting 20 years to 65 years.
- Sequential High-dose Dexamethasone and Response Adopted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Multicenter Phase 2 Study.
high dose dexamethsone

Multiple Myeloma Clinical Trial using Daratumumab; Lenalidomide; Dexamethasone

Genmab - Recruiting 18 years or older.
- An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma.
Daratumumab; Lenalidomide; Dexamethasone

Relapsed/Refractory Multiple Myeloma Clinical Trial using plitidepsin + dexamethasone; dexamethasone

PharmaMar - Recruiting 18 years or older.
- Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma.
plitidepsin + dexamethasone; dexamethasone

Multiple Myeloma Clinical Trial using carfilzomib and panobinostat

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma.
carfilzomib and panobinostat

Multiple Myeloma Clinical Trial

Centre Hospitalier Universitaire de Saint Etienne - Recruiting 18 years or older.
- Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study.

Myeloma Clinical Trial using Panobinostat; Bortezomib; Lenalidomide; Dexamethasone; Symptom Questionnaire

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM).
Panobinostat; Bortezomib; Lenalidomide; Dexamethasone; Symptom Questionnaire

Multiple Myeloma Clinical Trial using No drugs are involved

University of Arkansas - Recruiting 18 years or older.
- UARK 91-004 Therapeutic Research in Multiple Myeloma.
No drugs are involved

Multiple Myeloma Clinical Trial using Oprozomib; Melphalan; Prednisone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma.
Oprozomib; Melphalan; Prednisone

Multiple Myeloma, Neoplasms Clinical Trial using Vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers.
Vemurafenib

Multiple Myeloma Clinical Trial using Daratumumab 16 mg/kg (Part 1); Daratumumab 8 mg/kg (Part 1); Methylprednisolone; Acetaminophen; Diphenhydramine; Daratumumab (Part 2)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD.
Daratumumab 16 mg/kg (Part 1); Daratumumab 8 mg/kg (Part 1); Methylprednisolone; Acetaminophen; Diphenhydramine; Daratumumab (Part 2)

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Multiple Myeloma Clinical Trial using Oprozomib; Lenalidomide; Dexamethasone; Cyclophosphamide

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma.
Oprozomib; Lenalidomide; Dexamethasone; Cyclophosphamide

Myeloma Clinical Trial using Arry-520; Carfilzomib; Dexamethasone; Filgrastim

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma.
Arry-520; Carfilzomib; Dexamethasone; Filgrastim

Multiple Myeloma Clinical Trial using 4 mg Oral POM + 40 mg Oral DEX; 2 mg Oral POM + 40 mg Oral DEX

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics (PK) and Safety of Pomalidomide (POM) When Given in Combination With Low Dose Dexamethasone (LD-DEX) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Impaired Renal Function.
4 mg Oral POM + 40 mg Oral DEX; 2 mg Oral POM + 40 mg Oral DEX

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Hematologic Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Clinical Trial using Stem cell transplantation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases.
Stem cell transplantation

Multiple Myeloma, Leukemia, MGUS, or MBL Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 50 years or older.
- Study of Biomarkers of Exposure and Effects in Agriculture.

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphom Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol.

Multiple Myeloma Clinical Trial using Pomalidomide; stem cell; Dexamethasone; Clarithromycin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Autologous Stem Cell Transplant With Pomalidomide (CC-4047r) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium.
Pomalidomide; stem cell; Dexamethasone; Clarithromycin

Myeloma Clinical Trial using Minocycline; Placebo; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden During Maintenance Therapy for Multiple Myeloma.
Minocycline; Placebo; Questionnaires

Multiple Myeloma Clinical Trial using SAR650984; Lenalidomide

Sanofi - Recruiting 18 years or older.
- A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
SAR650984; Lenalidomide

Multiple Myeloma Clinical Trial using bortezomib (optimized retreatment); dexamethasone (optimized retreatment); bortezomib (standard retreatment); dexamethasone (standard retreatment)

Janssen-Cilag International NV - Recruiting 18 years or older.
- A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse..
bortezomib (optimized retreatment); dexamethasone (optimized retreatment); bortezomib (standard retreatment); dexamethasone (standard retreatment)

High-risk Smoldering Multiple Myeloma Clinical Trial using Siltuximab; Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma.
Siltuximab; Placebo

Solid Tumors, Lymphoma, or Multiple Myeloma Clinical Trial using CS-7017 and Bexarotene

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene.
CS-7017 and Bexarotene

Multiple Myeloma Clinical Trial using Bendamustine; Doxorubicin; Bortezomib; Filgrastim

Hoosier Oncology Group - Recruiting 18 years or older.
- A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma.
Bendamustine; Doxorubicin; Bortezomib; Filgrastim

Multiple Myeloma Clinical Trial

Bristol-Myers Squibb - Recruiting 18 years or older.
- Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE).

Myeloma Clinical Trial using Lenalidomide; MLN9708; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma.
Lenalidomide; MLN9708; Questionnaires

Myeloma Clinical Trial using Carfilzomib; Panobinostat

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma.
Carfilzomib; Panobinostat

Advanced Multiple Myeloma Clinical Trial using Carfilzomib, proteasome inhibitor; intravenous; ARRY-520, KSP(Eg5) inhibitor; intravenous; Dexamethasone, steroid; oral or intravenous; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Array BioPharma - Recruiting 18 years or older.
- .
Carfilzomib, proteasome inhibitor; intravenous; ARRY-520, KSP(Eg5) inhibitor; intravenous; Dexamethasone, steroid; oral or intravenous; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Multiple Myeloma Clinical Trial using Panobinostat; Carfilzomib; Dexamethasone

Emory University - Recruiting 18 years or older.
- A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma.
Panobinostat; Carfilzomib; Dexamethasone

Multiple Myeloma Clinical Trial using Nelfinavir; Lenalidomide; Dexamethasone

Swiss Group for Clinical Cancer Research - Recruiting 18 years or older.
- Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial.
Nelfinavir; Lenalidomide; Dexamethasone

Multiple Myeloma Clinical Trial using busulfan, melphalan and fludarabine

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years to 70 years.
- A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma.
busulfan, melphalan and fludarabine

Multiple Myeloma Clinical Trial

University of Arkansas - Recruiting 18 years or older.
- Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma.

Light Chain Deposition Disease (LCDD or MIDD), Light Chain and He Clinical Trial using Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Pilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis.
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone

Multiple Myeloma, or Auto Stem Cell Transplant Clinical Trial using Bortezomib

Hackensack University Medical Center - Recruiting 18 years to 75 years.
- Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma.
Bortezomib

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Relapsed and/or Refractory Multiple Myeloma Clinical Trial using Elotuzumab; Thalidomide; Dexamethasone; Cyclophosphamide

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma.
Elotuzumab; Thalidomide; Dexamethasone; Cyclophosphamide

Smoldering Multiple Myeloma Clinical Trial using Elotuzumab (BMS-901608; HuLuc63)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma.
Elotuzumab (BMS-901608; HuLuc63)

Newly Diagnosed, Previously Untreated Multiple Myeloma Clinical Trial using Lenalidomide; Dexamethasone; Elotuzumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma.
Lenalidomide; Dexamethasone; Elotuzumab

Multiple Myeloma Clinical Trial using Anti-CXCR4 (BMS-936564); Lenalidomide; Dexamethasone; Bortezomib

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.
Anti-CXCR4 (BMS-936564); Lenalidomide; Dexamethasone; Bortezomib

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, or Non-Hodg Clinical Trial using Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- An Open Label Randomized Phase II Study of Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.
Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Multiple Myeloma Clinical Trial using Total Marrow Irradiation; Autologous Transplant; Melphalan; Filgrastim (G-CSF)

University of Illinois at Chicago - Recruiting 18 years to 75 years.
- BMT-02: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Multiple Myeloma Following Initial Induction Therapy.
Total Marrow Irradiation; Autologous Transplant; Melphalan; Filgrastim (G-CSF)

Multiple Myeloma Clinical Trial using Ibrutinib; Carfilzomib; Placebo

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (KyprolisT) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma.
Ibrutinib; Carfilzomib; Placebo

Multiple Myeloma Clinical Trial using Oprozomib; Pomalidomide; Dexamethasone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects.
Oprozomib; Pomalidomide; Dexamethasone

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Multiple Myeloma, Relapsed, or Multiple Myeloma, Refractory to St Clinical Trial using Total Marrow Irradiation; Melphalan; Filgrastim (G-CSF)

University of Illinois at Chicago - Recruiting 18 years to 75 years.
- BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma.
Total Marrow Irradiation; Melphalan; Filgrastim (G-CSF)

Multiple Myeloma, Plasma Cell Leukemia Clinical Trial using ARRY-520, KSP(Eg5) inhibitor; intravenous; Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Dexamethasone, steroid; oral; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Array BioPharma - Recruiting 18 years or older.
- .
ARRY-520, KSP(Eg5) inhibitor; intravenous; Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Dexamethasone, steroid; oral; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Multiple Myeloma Clinical Trial using HuMax-CD38

Genmab - Recruiting 18 years or older.
- Daratumumab(HuMaxr-CD38)Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study.
HuMax-CD38

Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
Nivolumab

Multiple Myeloma Clinical Trial using Carfilzomib; Lenalidomide; Dexamethasone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study.
Carfilzomib; Lenalidomide; Dexamethasone

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Multiple Myeloma Clinical Trial using Pomalidomide; Bortezomib; Dexamethasone

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.
Pomalidomide; Bortezomib; Dexamethasone

Multiple Myeloma Clinical Trial using Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study.
Lenalidomide

Multiple Myeloma Clinical Trial using Carfilzomib; Lenalidomide; Dexamethasone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study.
Carfilzomib; Lenalidomide; Dexamethasone

Multiple Myeloma, or Leukemia, Plasma Cell Clinical Trial using Carfilzomib; Melphalan; Filgrastim

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma.
Carfilzomib; Melphalan; Filgrastim

Multiple Myeloma Clinical Trial using M-VTD-PACE; TT3-LITE Regimen (L-TT3)

University of Arkansas - Recruiting 18 years to 75 years.
- UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma: A Randomized Trial Comparing Standard Total Therapy 3 (S-TT3) With TT3-LITE (L-TT3).
M-VTD-PACE; TT3-LITE Regimen (L-TT3)

Multiple Myeloma Clinical Trial

University of Arkansas - Recruiting 18 years to 95 years.
- Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes.

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using bortezomib; dexamethasone

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy.
bortezomib; dexamethasone

Multiple Myeloma Clinical Trial using Bendamustine; Pomalidomide; Dexamethasone

Duke University - Recruiting 18 years or older.
- A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Bendamustine; Pomalidomide; Dexamethasone

Multiple Myeloma Clinical Trial using Velcade; Cyclophosphamide; Revlimid

Duke University - Recruiting 18 years or older.
- Phase II Subcutaneous VELCADE and Oral Cyclophosphamide-based Induction + Sequential VELCADE and Revlimid Maintenance for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen.
Velcade; Cyclophosphamide; Revlimid

Asymptomatic Multiple Myeloma Clinical Trial using ENK Cell Infusion

University of Arkansas - Recruiting 18 years to 75 years.
- A Phase II Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma.
ENK Cell Infusion

Multiple Myeloma, or Peripheral Neuropathy Clinical Trial

Oncotherapeutics - Recruiting 18 years or older.
- Correlation Between Serum Vitamin D Levels and the Incidence of Peripheral Neuropathy Among Multiple Myeloma Patients Who Have Previously Received Treatment With Bortezomib or Thalidomide.

Multiple Myeloma Clinical Trial using Carfilzomib; Bortezomib; Melphalan; Prednisone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma.
Carfilzomib; Bortezomib; Melphalan; Prednisone

Relapsed Multiple Myeloma, or End-stage Renal Disease Clinical Trial using Carfilzomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease.
Carfilzomib

Multiple Myeloma Clinical Trial using carfilzomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1/2, Multicenter, Single-arm, Nonrandomized, Open-label and Dose-escalation Study of Weekly Carfilzomib and Dexamethasone (Cd-qw) for Patients With Progressive Multiple Myeloma..
carfilzomib

Multiple Myeloma Clinical Trial using busulfan; melphalan; fludarabine; anti-thymocyte globulin (ATG); a T cell depleted stem cell transplant

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years to 69 years.
- A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma.
busulfan; melphalan; fludarabine; anti-thymocyte globulin (ATG); a T cell depleted stem cell transplant

Multiple Myeloma Clinical Trial using Carfilzomib in combination with cyclophosphamide and dexamethasone (CCd); Cyclophosphamide; Dexamethasone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- A Multicenter, Open-label, Phase 1/2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone Induction Followed by Randomization to Carfilzomib Maintenance Versus Observation in Newly Diagnosed Multiple Myeloma Subjects (CHAMPION 2).
Carfilzomib in combination with cyclophosphamide and dexamethasone (CCd); Cyclophosphamide; Dexamethasone

Relapsed/Refractory Multiple Myeloma Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma.
ABT-199

Multiple Myeloma, Myelodysplastic Syndrome, Hodgkin's Lymphoma, o Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies.
MK-3475

Multiple Myeloma Clinical Trial using Thalidomide; Bortezomib

Janssen Scientific Affairs, LLC - Recruiting 18 years or older.
- An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant.
Thalidomide; Bortezomib

Multiple Myeloma Clinical Trial using Oprozomib; Dexamethasone

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Oprozomib; Dexamethasone

Myeloma, Bortezomib, Cyclophosphamide, Dexamethasone, or Granuloc Clinical Trial using G-CSF; Bortezomib; Cyclophosphamide; Dexamethasone

The Second Affiliated Hospital of Soochow University - Recruiting 18 years to 80 years.
- Phase ? Study of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma.
G-CSF; Bortezomib; Cyclophosphamide; Dexamethasone

Multiple Myeloma, or Waldenstrom Macroglobulinemia Clinical Trial using oprozomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies.
oprozomib

Multiple Myeloma Clinical Trial using PCV13

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma.
PCV13

Refractory Multiple Myeloma Clinical Trial using carfilzomib; dexamethasone; laboratory biomarker analysis

Indiana University - Recruiting 18 years or older.
- A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy.
carfilzomib; dexamethasone; laboratory biomarker analysis

Multiple Myeloma Clinical Trial using lenalidomide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Clinical Trial of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance.
lenalidomide

Myeloma Clinical Trial using Lenalidomide; Melphalan; NK Cell Infusion; Interleukin-2; Stem Cell Infusion; G-CSF

M.D. Anderson Cancer Center - Recruiting 18 years to 75 years.
- Phase I/II Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma.
Lenalidomide; Melphalan; NK Cell Infusion; Interleukin-2; Stem Cell Infusion; G-CSF

Multiple Myeloma Clinical Trial using DKN-01 300 mg; DKN-01 600 mg; Standard of Care

Dekkun Corporation - Recruiting 30 years or older.
- A Pilot Study of DKN-01 and Lenalidomide (Revlimidr)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
DKN-01 300 mg; DKN-01 600 mg; Standard of Care

Multiple Myeloma Clinical Trial using Bortezomib; dexamethasone; Fludarabine; Melphalan

PETHEMA Foundation - Recruiting 18 years to 66 years.
- MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning.
Bortezomib; dexamethasone; Fludarabine; Melphalan

Multiple Myeloma Clinical Trial using Fludarabine monophosphate, melphalan, Bortezomib

Hackensack University Medical Center - Recruiting 18 years to 69 years.
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib.
Fludarabine monophosphate, melphalan, Bortezomib

Multiple Myeloma Clinical Trial using PCI-32765; Dexamethasone

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma.
PCI-32765; Dexamethasone

Multiple Myeloma Clinical Trial using Subcutaneous bortezomib

Oncotherapeutics - Recruiting 18 years or older.
- A Phase II Study of Subcutaneous (SC) Bortezomib-Regimens for Patients With Relapsed/Refractory Multiple Myeloma (MM) Failing Prior Intravenous (IV) Bortezomib-Containing Regimens.
Subcutaneous bortezomib

Multiple Myeloma Clinical Trial using SST0001

Sigma Tau Research Switzerland SA - Recruiting 18 years or older.
- Phase I Dose Finding Study Assessing Safety and Tolerability of SST0001 in Advanced Multiple Myeloma..
SST0001

Relapsed or Refractory Multiple Myeloma Clinical Trial using dexamethasone; carfilzomib

Southwest Oncology Group - Recruiting 18 years or older.
- S1304, A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease.
dexamethasone; carfilzomib

Multiple Myeloma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma.
MLN9708

Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, or Renal Canc Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders.

Lymphoma, Myeloma, or Leukemia Clinical Trial using Kappa CD28 T cells

Baylor College of Medicine - Recruiting 18 years or older.
- Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With Chronic Lymphocytic Leukemia, B-Cell Lymphoma or Multiple Myeloma.
Kappa CD28 T cells

Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II M Clinical Trial using romiplostim

New York University School of Medicine - Recruiting 18 years or older.
- Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma.
romiplostim

Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodys Clinical Trial using Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Masonic Cancer Center, University of Minnesota - Recruiting 1 year to 70 years.
- Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant.
Donor Lymphocyte Infusion; Induction Chemotherapy + DLI

Multiple Myeloma Clinical Trial using Carfilzomib; Cyclophosphamide; Dexamethasone

Academic Myeloma Consortium - Recruiting 18 years or older.
- A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma.
Carfilzomib; Cyclophosphamide; Dexamethasone

Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Lymphoma Clinical Trial using Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG); Stem Cell Transplant; Stem Cells Collections; Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI); Fludarabine, Busulfan, and ATG

University of Chicago - Recruiting 1 year or older.
- Combined Haploidentical-Cord Blood Transplantation for Adults and Children.
Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG); Stem Cell Transplant; Stem Cells Collections; Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI); Fludarabine, Busulfan, and ATG

Stage I Multiple Myeloma, Stage II Multiple Myeloma, or Stage III Clinical Trial using dexamethasone; carfilzomib; lenalidomide; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy.
dexamethasone; carfilzomib; lenalidomide; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Brain and Central Nervous System Tumors, Chronic Myeloproliferati Clinical Trial using 3'-deoxy-3'-[18F]fluorothymidine

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET).
3'-deoxy-3'-[18F]fluorothymidine

Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Clinical Trial using assessment of therapy complications

Southwest Oncology Group - Recruiting N/A or older.
- S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment.
assessment of therapy complications

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using clonality analysis; polymerase chain reaction; protein analysis; biologic sample preservation procedure; laboratory biomarker analysis; fluorescence spectroscopy; quality-of-life assessment

Boston Medical Center - Recruiting 18 years or older.
- Data, Tissue, Blood, and Urine Repository for Amyloid Diseases.
clonality analysis; polymerase chain reaction; protein analysis; biologic sample preservation procedure; laboratory biomarker analysis; fluorescence spectroscopy; quality-of-life assessment

Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multipl Clinical Trial using SNS01-T

Senesco Technologies, Inc. - Recruiting 18 years or older.
- Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma.
SNS01-T

Multiple Myeloma Clinical Trial

Washington University School of Medicine - Recruiting 65 years or older.
- Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma.

Multiple Myeloma Clinical Trial using PRLX 93936

Prolexys Pharmaceuticals - Recruiting 18 years or older.
- Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma.
PRLX 93936

Multiple Myeloma Clinical Trial using NPI-0052

Triphase Research and Development I Corporation - Recruiting 18 years or older.
- Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma.
NPI-0052

Multiple Myeloma Clinical Trial

Medical University of South Carolina - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma.

Multiple Myeloma Clinical Trial using Busulfan; Melphalan; Lenalidomide

University Health Network, Toronto - Recruiting 18 years to 75 years.
- A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression..
Busulfan; Melphalan; Lenalidomide

Multiple Myeloma Clinical Trial using Lenalidomide; Dexamethasone

University of Pittsburgh - Recruiting 18 years or older.
- A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma.
Lenalidomide; Dexamethasone

Multiple Myeloma Clinical Trial using masitinib 6 mg/kg/day; placebo

AB Science - Recruiting 18 years or older.
- A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase 3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day in Combination With Bortezomib and Dexamethasone to Placebo in Combination With Bortezomib and Dexamethasone in the Treatment of Patients With Relapsing Multiple Myeloma Who Received One Previous Therapy.
masitinib 6 mg/kg/day; placebo

Multiple Myeloma Clinical Trial using ACT PET/CT

Chang Gung Memorial Hospital - Recruiting 20 years or older.
- C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment.
ACT PET/CT

Multiple Myeloma Clinical Trial using ACY-1215

Acetylon Pharmaceuticals Incorporated - Recruiting 18 years or older.
- A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma.
ACY-1215

Nodal Lymphoma, Lymphoma With Cutaneous Involvement, Lymphoma in Clinical Trial using panobinostat

Peter MacCallum Cancer Centre, Australia - Recruiting 18 years or older.
- A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy.
panobinostat

Multiple Myeloma Clinical Trial using Autologous bone marrow transplantation; Allogeneic bone marrow transplantation

Tehran University of Medical Sciences - Recruiting 18 years to 55 years.
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma.
Autologous bone marrow transplantation; Allogeneic bone marrow transplantation

Multiple Myeloma Clinical Trial using depsipeptide; bortezomib; dexamethasone

Peter MacCallum Cancer Centre, Australia - Recruiting 18 years or older.
- A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma.
depsipeptide; bortezomib; dexamethasone

Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Clinical Trial using CX-4945 oral formulation

Cylene Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma.
CX-4945 oral formulation

Multiple Myeloma Clinical Trial using Intake of 60 ml placebo daily in addition to chemotherapy; Intake of 60 ml agaricus daily in addition to chemotherapy

Oslo University Hospital - Recruiting N/A or older.
- Use of the Medicinal Mushroom Agaricus Blazei Murill in Addition to High Dose Chemotherapy in Patients With Multiple Myeloma..
Intake of 60 ml placebo daily in addition to chemotherapy; Intake of 60 ml agaricus daily in addition to chemotherapy

Multiple Myeloma Clinical Trial using Bortezomib,Pirarubicin,Dexamethasone; Thalidomide,Pirarubicin,Dexamethasone

Second Military Medical University - Recruiting 18 years or older.
- Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes.
Bortezomib,Pirarubicin,Dexamethasone; Thalidomide,Pirarubicin,Dexamethasone

Multiple Myeloma, Cast Nephropathy, or Kidney Failure Clinical Trial using FLC removal HD (Gambro HCO 1100); Standard dialysis on a high flux ployflux dialyser

University Hospital Birmingham - Recruiting 18 years or older.
- European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy.
FLC removal HD (Gambro HCO 1100); Standard dialysis on a high flux ployflux dialyser

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, or Multiple Myeloma Clinical Trial using Total Body Irradiation; Fludarabine; Recipient Leukocyte Infusion

Massachusetts General Hospital - Recruiting 18 years to 74 years.
- Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation.
Total Body Irradiation; Fludarabine; Recipient Leukocyte Infusion

Multiple Myeloma Clinical Trial using Cyclophosphamide; Lenalidomide; Dexamethasone; Melphalan

Fondazione Neoplasie Sangue Onlus - Recruiting 18 years to 65 years.
- A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects.
Cyclophosphamide; Lenalidomide; Dexamethasone; Melphalan

Multiple Myeloma Clinical Trial using Total Marrow Irradiation

Ottawa Hospital Research Institute - Recruiting 18 years to 60 years.
- A Dose Escalation Study of Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).
Total Marrow Irradiation

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using bortezomib; hydroxychloroquine; immunologic technique; laboratory biomarker analysis; mass spectrometry; pharmacological study; biopsy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma.
bortezomib; hydroxychloroquine; immunologic technique; laboratory biomarker analysis; mass spectrometry; pharmacological study; biopsy

Multiple Myeloma Clinical Trial using Fluphenazine HCl

Immune Control - Recruiting 18 years or older.
- Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Fluphenazine HCl

Multiple Myeloma Clinical Trial using Thalidomide

Korean Multiple Myeloma Working Party - Recruiting 18 years to 75 years.
- Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients.
Thalidomide

Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lym Clinical Trial using Tacrolimus and MMF

Colorado Blood Cancer Institute - Recruiting 50 years to 70 years.
- Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Family Donor Hematopoietic Cell Transplants.
Tacrolimus and MMF

Multiple Myeloma Clinical Trial using velcade

Korean Multiple Myeloma Working Party - Recruiting 15 years to 65 years.
- Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM.
velcade